Tango Therapeutics (TNGX) Accumulated Expenses (2020 - 2025)
Historic Accumulated Expenses for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $13.1 million.
- Tango Therapeutics' Accumulated Expenses fell 1261.5% to $13.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.1 million, marking a year-over-year decrease of 1261.5%. This contributed to the annual value of $16.5 million for FY2024, which is 711.64% up from last year.
- Latest data reveals that Tango Therapeutics reported Accumulated Expenses of $13.1 million as of Q3 2025, which was down 1261.5% from $11.5 million recorded in Q2 2025.
- Tango Therapeutics' Accumulated Expenses' 5-year high stood at $17.5 million during Q4 2022, with a 5-year trough of $202089.0 in Q1 2021.
- In the last 5 years, Tango Therapeutics' Accumulated Expenses had a median value of $13.1 million in 2025 and averaged $11.9 million.
- Per our database at Business Quant, Tango Therapeutics' Accumulated Expenses surged by 1331237.2% in 2021 and then tumbled by 3138.19% in 2025.
- Tango Therapeutics' Accumulated Expenses (Quarter) stood at $9.9 million in 2021, then skyrocketed by 76.95% to $17.5 million in 2022, then dropped by 11.97% to $15.4 million in 2023, then grew by 7.12% to $16.5 million in 2024, then decreased by 20.51% to $13.1 million in 2025.
- Its Accumulated Expenses stands at $13.1 million for Q3 2025, versus $11.5 million for Q2 2025 and $10.4 million for Q1 2025.